article Open AccessTop 1% cited

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors

Clinical Pharmacology & Therapeutics · 2015 · Vol. 98(2) · pp. 127–134

J K Hicks(Cleveland Clinic)JR Bishop(University of Minnesota)Katrin Sangkuhl(Stanford University)Müller Dj(Centre for Addiction and Mental Health)Yuan Ji(Mayo Clinic)SG Leckband(VA San Diego Healthcare System)JS Leeder(University of Missouri–Kansas City)RL Graham(Veterans Health Administration)DL ChiulliAdrián LLerena(Universidad de Extremadura)TC Skaar(Indiana University School of Medicine)Stuart A. Scott(Icahn School of Medicine at Mount Sinai)Julia Stingl(Federal Institute for Drugs and Medical Devices)Teri E. Klein(Stanford University)KE Caudle(St. Jude Children's Research Hospital)Andrea Gaedigk✉(University of Missouri–Kansas City)

View via DOI Full-text PDF

Abstract

Selective serotonin reuptake inhibitors (SSRIs) are primary treatment options for major depressive and anxiety disorders. CYP2D6 and CYP2C19 polymorphisms can influence the metabolism of SSRIs, thereby affecting drug efficacy and safety. We summarize evidence from the published literature supporting these associations and provide dosing recommendations for fluvoxamine, paroxetine, citalopram, escitalopram, and sertraline based on CYP2D6 and/or CYP2C19 genotype (updates at www.pharmgkb.org).

Pharmacogenetics and Drug Metabolism Treatment of Major Depression Receptor Mechanisms and SignalingFluvoxamineEscitalopramCitalopramCYP2C19ParoxetinePharmacogeneticsSertralineDosingMedicinePharmacology

MeSH terms

BiotransformationGenotypeHumansPharmacogeneticsPhenotypePolymorphism, GeneticRisk FactorsSelective Serotonin Reuptake InhibitorsRisk AssessmentCytochrome P-450 CYP2D6Drug Dosage CalculationsPatient SafetyCytochrome P-450 CYP2C19

Citations

958

FWCI

84.40

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update